Guest

Dr. Ethan Perlstein

Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new drugs in model organisms called evolutionary pharmacology. Ethan is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.

Appears in 1 Episode

Biotech on the Blockchain: Rare Disease Solutions with Dr. Ethan Perlstein

#4 Apr 15, 25

Biotech on the Blockchain: Rare Disease Solutions with Dr. Ethan Perlstein

In this episode, we interview Dr. Ethan Perlstein, founder and CEO of Curetopia, about his mission to end rare genetic diseases. Dr. Perlstein shares his journey as a scientist, builder, and investor, and discusses Curetopia's innovative approach to drug development, including the use of blockchain and Web3 technologies. He emphasizes the urgency of addressing rare diseases and the need for new models to accelerate the search for cures.Chapters/Timestamps:00:00 - Introduction and Dr. Ethan Perlstein's Background 08:50 - The Challenge of Rare Diseases 21:25 - Curetopia's Mission and Approach 31:54 - Blockchain and the Future of Drug Development 40:09 - The Future of Curetopia and Rare Disease ResearchGuest Information:Guest's Name: Dr. Ethan PerlsteinGuest's Title/Position: Founder and CEOCompany/Affiliation: CuretopiaGuest's Bio: Dr. Ethan Perlstein is a scientist, builder, and investor with a focus on developing cures for rare genetic diseases. He is the founder and CEO of Curetopia, a company utilizing innovative approaches to drug development and funding.Links and Resources:Curetopia Website: https://www.curetopia.xyz/Curetopia on Telegram: https://t.me/curetopiaCuretopia on X (Twitter): https://x.com/endrarediseasesKey Takeaways/Highlights:Dr. Perlstein's background as a scientist and his transition into building and investing in biotech companies.The challenges and misconceptions surrounding rare diseases, including their prevalence and the lack of financial incentive for research.Dr. Perlstein's motivation for focusing on rare diseases, inspired by his interaction with parents of affected children.Curetopia's mission to end rare diseases through innovative drug development strategies.The potential of blockchain and Web3 technologies to transform drug development, including funding, data sharing, and community engagement.Dr. Perlstein's vision for a more collaborative and accelerated approach to finding cures for rare diseases.